Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
UNICANCER
Roswell Park Cancer Institute
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Ludwig Institute for Cancer Research
AstraZeneca